501 related articles for article (PubMed ID: 15090564)
1. Multicentre, randomised, double blind, placebo controlled, phase III study of weekly, low dose, subcutaneous interferon beta-1a in secondary progressive multiple sclerosis.
Andersen O; Elovaara I; Färkkilä M; Hansen HJ; Mellgren SI; Myhr KM; Sandberg-Wollheim M; Soelberg Sørensen P
J Neurol Neurosurg Psychiatry; 2004 May; 75(5):706-10. PubMed ID: 15090564
[TBL] [Abstract][Full Text] [Related]
2. Full results of the Evidence of Interferon Dose-Response-European North American Comparative Efficacy (EVIDENCE) study: a multicenter, randomized, assessor-blinded comparison of low-dose weekly versus high-dose, high-frequency interferon beta-1a for relapsing multiple sclerosis.
Schwid SR; Panitch HS
Clin Ther; 2007 Sep; 29(9):2031-48. PubMed ID: 18035202
[TBL] [Abstract][Full Text] [Related]
3. Benefit of interferon beta-1a on MSFC progression in secondary progressive MS.
Cohen JA; Cutter GR; Fischer JS; Goodman AD; Heidenreich FR; Kooijmans MF; Sandrock AW; Rudick RA; Simon JH; Simonian NA; Tsao EC; Whitaker JN;
Neurology; 2002 Sep; 59(5):679-87. PubMed ID: 12221157
[TBL] [Abstract][Full Text] [Related]
4. Once-weekly 22microg subcutaneous IFN-beta-1a in secondary progressive MS: a 3-year follow-up study on brain MRI measurements and serum MMP-9 levels.
Wu X; Kuusisto H; Dastidar P; Huhtala H; Nikkari ST; Ukkonen M; Höyhtyä M; Elovaara I
Acta Neurol Scand; 2007 Jul; 116(1):43-8. PubMed ID: 17587254
[TBL] [Abstract][Full Text] [Related]
5. Interferon-beta-1b: a review of its use in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
CNS Drugs; 2004; 18(8):521-46. PubMed ID: 15182221
[TBL] [Abstract][Full Text] [Related]
6. Comparison of two dosing frequencies of subcutaneous interferon beta-1a in patients with a first clinical demyelinating event suggestive of multiple sclerosis (REFLEX): a phase 3 randomised controlled trial.
Comi G; De Stefano N; Freedman MS; Barkhof F; Polman CH; Uitdehaag BM; Casset-Semanaz F; Hennessy B; Moraga MS; Rocak S; Stubinski B; Kappos L
Lancet Neurol; 2012 Jan; 11(1):33-41. PubMed ID: 22146409
[TBL] [Abstract][Full Text] [Related]
7. Spotlight on Interferon-beta-1b in relapsing-remitting and secondary progressive multiple sclerosis.
McCormack PL; Scott LJ
BioDrugs; 2004; 18(5):343-7. PubMed ID: 15377176
[TBL] [Abstract][Full Text] [Related]
8. Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.
Filippini G; Del Giovane C; Clerico M; Beiki O; Mattoscio M; Piazza F; Fredrikson S; Tramacere I; Scalfari A; Salanti G
Cochrane Database Syst Rev; 2017 Apr; 4(4):CD012200. PubMed ID: 28440858
[TBL] [Abstract][Full Text] [Related]
9. Interferon beta for secondary progressive multiple sclerosis.
La Mantia L; Vacchi L; Di Pietrantonj C; Ebers G; Rovaris M; Fredrikson S; Filippini G
Cochrane Database Syst Rev; 2012 Jan; 1():CD005181. PubMed ID: 22258960
[TBL] [Abstract][Full Text] [Related]
10. Mitoxantrone: a review of its use in multiple sclerosis.
Scott LJ; Figgitt DP
CNS Drugs; 2004; 18(6):379-96. PubMed ID: 15089110
[TBL] [Abstract][Full Text] [Related]
11. Long-term subcutaneous interferon beta-1a therapy in patients with relapsing-remitting MS.
Kappos L; Traboulsee A; Constantinescu C; Erälinna JP; Forrestal F; Jongen P; Pollard J; Sandberg-Wollheim M; Sindic C; Stubinski B; Uitdehaag B; Li D
Neurology; 2006 Sep; 67(6):944-53. PubMed ID: 17000959
[TBL] [Abstract][Full Text] [Related]
12. Randomized controlled trial of interferon- beta-1a in secondary progressive MS: Clinical results.
Secondary Progressive Efficacy Clinical Trial of Recombinant Interferon-Beta-1a in MS (SPECTRIMS) Study Group
Neurology; 2001 Jun; 56(11):1496-504. PubMed ID: 11402106
[TBL] [Abstract][Full Text] [Related]
13. Randomised double-blind placebo-controlled study of interferon beta-1a in relapsing/remitting multiple sclerosis. PRISMS (Prevention of Relapses and Disability by Interferon beta-1a Subcutaneously in Multiple Sclerosis) Study Group.
Lancet; 1998 Nov; 352(9139):1498-504. PubMed ID: 9820297
[TBL] [Abstract][Full Text] [Related]
14. A randomized, double-blind, dose-comparison study of weekly interferon beta-1a in relapsing MS.
Clanet M; Radue EW; Kappos L; Hartung HP; Hohlfeld R; Sandberg-Wollheim M; Kooijmans-Coutinho MF; Tsao EC; Sandrock AW;
Neurology; 2002 Nov; 59(10):1507-17. PubMed ID: 12451189
[TBL] [Abstract][Full Text] [Related]
15. Interferon beta-1b in secondary progressive MS: results from a 3-year controlled study.
Panitch H; Miller A; Paty D; Weinshenker B;
Neurology; 2004 Nov; 63(10):1788-95. PubMed ID: 15557491
[TBL] [Abstract][Full Text] [Related]
16. [Interferon beta-1b for treatment of secondary chronic progressive multiple sclerosis].
Zimmermann C; Walther EU; Goebels N; Lienert C; Kappos L; Hartung HP; Hohlfeld R
Nervenarzt; 1999 Aug; 70(8):759-63. PubMed ID: 10483579
[TBL] [Abstract][Full Text] [Related]
17. Randomized controlled trial of interferon-beta-1a in secondary progressive MS: MRI results.
Li DK; Zhao GJ; Paty DW;
Neurology; 2001 Jun; 56(11):1505-13. PubMed ID: 11402107
[TBL] [Abstract][Full Text] [Related]
18. Methylprednisolone in combination with interferon beta-1a for relapsing-remitting multiple sclerosis (MECOMBIN study): a multicentre, double-blind, randomised, placebo-controlled, parallel-group trial.
Ravnborg M; Sørensen PS; Andersson M; Celius EG; Jongen PJ; Elovaara I; Bartholomé E; Constantinescu CS; Beer K; Garde E; Sperling B
Lancet Neurol; 2010 Jul; 9(7):672-80. PubMed ID: 20542736
[TBL] [Abstract][Full Text] [Related]
19. Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.
De Stefano N; Comi G; Kappos L; Freedman MS; Polman CH; Uitdehaag BM; Hennessy B; Casset-Semanaz F; Lehr L; Stubinski B; Jack DL; Barkhof F
J Neurol Neurosurg Psychiatry; 2014 Jun; 85(6):647-53. PubMed ID: 24292999
[TBL] [Abstract][Full Text] [Related]
20. Placebo-controlled multicentre randomised trial of interferon beta-1b in treatment of secondary progressive multiple sclerosis. European Study Group on interferon beta-1b in secondary progressive MS.
Lancet; 1998 Nov; 352(9139):1491-7. PubMed ID: 9820296
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
